November 14, 2008Cardiology
Effect of Sotalol on Arrhythmias and Exercise Tolerance in Patients with Hypertrophic Cardiomyopathy
Key result
Sotalol significantly improved exercise time compared to placebo (10.6 vs 9.4 min; p<0.01) and suppressed supraventricular and ventricular arrhythmias in patients with hypertrophic cardiomyopathy.
Why the study?
Does sotalol improve exercise tolerance and reduce arrhythmias in patients with hypertrophic cardiomyopathy?
Population
30 patients with hypertrophic cardiomyopathy (HCM)
Comparison
Sotalol vs Placebo (in the short-term cross-over phase)
Design
RCT, cross-over, double-blind (short-term phase), open-label (6-month phase)
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Sotalol may be considered to improve exercise tolerance and suppress arrhythmias in HCM; extends randomized evidence for its role in this population.
Study Design
Type
RCT (n=30)
Blinding
Double-blind
Structured PICO
Does sotalol improve exercise tolerance and reduce arrhythmias in patients with hypertrophic cardiomyopathy?
P
Population
30 patients with hypertrophic cardiomyopathy (HCM)
I
Intervention
Sotalol (320 mg/day in short-term phase, 160-480 mg/day in 6-month open-label phase)
C
Comparator
Placebo (in the short-term cross-over phase)
O
Outcome
Exercise tolerance (exercise time) and incidence of supraventricular and ventricular arrhythmiassurrogate
Main Result
Absolute Event Rate: 10.6% vs 9.4%
p-value: p=< 0.01
Sotalol significantly improves exercise tolerance and suppresses supraventricular and ventricular arrhythmias in patients with hypertrophic cardiomyopathy.
Cite This Study
Tendera et al. (2008) conducted an RCT in Hypertrophic cardiomyopathy (n=30). Sotalol vs. Placebo was evaluated on Exercise time (p=< 0.01). Sotalol significantly improved exercise time compared to placebo (10.6 vs 9.4 min; p<0.01) and suppressed supraventricular and ventricular arrhythmias in patients with hypertrophic cardiomyopathy.